How to Prescribe Zepbound (Tirzepatide) for a 72-Year-Old Obese Female
Start tirzepatide at 2.5 mg subcutaneously once weekly, escalate to 5 mg after 4 weeks, then increase by 2.5 mg increments every 4 weeks as tolerated, targeting a maintenance dose of 10-15 mg weekly for maximal weight loss. 1
Dosing Algorithm
Initial Dosing
- Week 0-4: Begin with 2.5 mg subcutaneously once weekly
- Week 5-8: Increase to 5 mg once weekly
- Week 9-12: Increase to 7.5 mg once weekly
- Week 13-16: Increase to 10 mg once weekly
- Week 17-20: Increase to 12.5 mg once weekly (if tolerated and additional weight loss needed)
- Week 21+: Increase to 15 mg once weekly (maximum dose)
The dose escalation schedule is critical—rushing through escalation increases gastrointestinal side effects and treatment discontinuation. 2
Target Maintenance Dose
Aim for 10-15 mg weekly for optimal outcomes. At 72 weeks, the 15 mg dose produces mean weight loss of 20.9%, the 10 mg dose produces 19.5%, and the 5 mg dose produces 15.0% weight reduction. 1 Recent evidence shows that even 2.5 mg may produce substantial weight loss (~15%) when combined with lifestyle intervention, though this was studied in younger Japanese adults. 3
Expected Outcomes
Weight Loss Efficacy
- 15 mg dose: 91% of patients achieve ≥5% weight loss, 57% achieve ≥20% weight loss 2
- 10 mg dose: 89% achieve ≥5% weight loss, 50% achieve ≥20% weight loss 2
- Mean weight reduction at 72 weeks ranges from 15-21% depending on final dose 1
Cardiometabolic Benefits
Beyond weight loss, tirzepatide significantly improves:
- HbA1c reduction (important even in non-diabetics for diabetes prevention)
- Blood pressure reduction (systolic BP drops ~12.6 mmHg) 4
- Lipid profile improvements (total cholesterol, triglycerides, non-HDL cholesterol) 4
- Diabetes prevention: Only 1.3% of patients with prediabetes developed diabetes over 176 weeks versus 13.3% with placebo 5
Critical Safety Considerations for a 72-Year-Old
Gastrointestinal Side Effects (Most Common)
- Nausea, diarrhea, and vomiting occur primarily during dose escalation (first 20 weeks) 1, 2
- These are typically mild-to-moderate and resolve with continued treatment
- Mitigation strategy: Slow dose escalation, anti-emetics as needed, dietary modifications (smaller meals, avoid high-fat foods)
- Treatment discontinuation due to adverse events: 4.3-7.1% depending on dose 2
Age-Specific Concerns
While the pivotal trials included adults up to age 65+, specific data in patients >70 years is limited. However:
- No increased serious adverse events compared to placebo in available trials 2
- Monitor for dehydration from GI side effects, especially critical in elderly patients
- Assess renal function at baseline and periodically (elderly have reduced renal reserve)
- Screen for gastroparesis symptoms before initiating (relative contraindication)
Contraindications to Screen For
- Personal or family history of medullary thyroid carcinoma
- Multiple endocrine neoplasia syndrome type 2
- History of pancreatitis (use with extreme caution; monitor lipase if symptoms develop) 6
- Severe gastroparesis
Monitoring Protocol
Baseline Assessment
- Weight, BMI, waist circumference
- Blood pressure
- Fasting glucose and HbA1c (screen for diabetes/prediabetes)
- Lipid panel
- Renal function (creatinine, eGFR)
- Thyroid function if clinically indicated
- Screen for contraindications listed above
Follow-Up Schedule
- Weeks 4,8,12,16,20: Assess tolerability, adjust dose, monitor weight
- Every 12 weeks thereafter: Weight, blood pressure, metabolic parameters
- Annually: Comprehensive metabolic panel, lipids, HbA1c
Lifestyle Intervention (Non-Negotiable)
Tirzepatide works synergistically with lifestyle modification. All patients in efficacy trials received:
- Reduced-calorie diet (500 kcal/day deficit)
- Physical activity counseling (≥150 minutes/week moderate activity)
- Regular behavioral counseling sessions 2
Real-world data shows excellent adherence to dietary therapy (96.4%) significantly enhances outcomes. 3
Duration of Treatment
Obesity is a chronic disease requiring long-term treatment. 1 The 3-year SURMOUNT-1 extension data demonstrates:
- Sustained weight loss through 176 weeks of treatment 5
- After 17 weeks off treatment, significant weight regain occurs 5
- Recommendation: Plan for indefinite treatment unless contraindications develop
Comparative Context
Tirzepatide produces superior weight loss compared to other anti-obesity medications:
- 5.1% greater weight loss than semaglutide 2.4 mg weekly 1
- 13.0% greater weight loss than liraglutide 3 mg daily 1
- Substantially more effective than phentermine-topiramate or naltrexone-bupropion 1
Common Pitfalls to Avoid
- Escalating dose too quickly: This is the primary cause of treatment discontinuation due to GI side effects
- Inadequate patient education: Patients must understand GI symptoms are temporary and typically resolve
- Stopping at 5 mg: While effective, 10-15 mg produces significantly greater weight loss
- Discontinuing due to mild nausea: Most GI symptoms are self-limited; consider anti-emetics before stopping
- Neglecting lifestyle intervention: Medication alone is less effective than combined therapy
- Not planning for long-term treatment: Stopping medication leads to weight regain
Storage and Administration
- Administer subcutaneously in abdomen, thigh, or upper arm
- Rotate injection sites
- Do not freeze 7
- Store in refrigerator; can be kept at room temperature for up to 21 days